logo-loader
Ceapro Inc.

Ceapro to begin clinical trials for beta glucan to treat high cholesterol

Ceapro Inc (CVE: CZO) CEO Gilles Gagnon tells Proactive Investors the company will soon begin enrollment in clinical trials of its cholesterol-fighting beta glucan.

Meanwhile, the Canadian-based biotech company's recent positive findings indicate its PGX Technology can be used as a delivery system for use on the skin or as a fast-acting oral drug.

Quick facts: Ceapro Inc.

Price: $0.36

Market: TSX-V
Market Cap: $27.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks lag but Weekend Unlimited shares jump as it...

Buds today are Weekend Unlimited Inc (CSE:POT) (OTCMKTS:WKULF), Pressure BioSciences Inc (OTCMKTS:PBIO). Duds are Tilray Inc (NASDAQ:TLRY), CannTrust Holdings Inc (TSE:TRST) (NYSE:CTST). 

2 hours, 14 minutes ago

2 min read